Evidence map›Paper›PMID 42381485›Full record

ArticleBritish journal of haematology2026

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

Andreas Katsimigas, Mikkel Werling, Casper M Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben-Dali, Mariam H Hleuhel, Christian Brieghel, Carsten U Niemann, Caspar da Cunha-Bang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andreas KatsimigasDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0009-0005-8348-1907
Mikkel WerlingDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Casper M FrederiksenDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Noomi VainerDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Klaus RostgaardHematology Branch, Danish Cancer Institute, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-6220-9414
Yasmin Ben-DaliDepartment of Surgery, Herlev Hospital, Herlev, Denmark.
Mariam H HleuhelLægehuset Skælvænget, Assens, Denmark.
Christian BrieghelDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-1816-8106
Carsten U NiemannDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Caspar da Cunha-BangDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

Funding

genmab
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) type Richter transformation (DLBCL-RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL-RT with or without previous CLL-directed therapy compared to dnDLBCL between 2002 and 2022. We included 6525 patients with dnDLBCL and 383 patients with DLBCL-RT, of whom 260 had Richter transformed treatment-naïve CLL (RT:TN-CLL) and 123 had Richter transformed treatment exposed CLL (RT:TE-CLL). Median time to next treatment or death (TTNTd) was 4.83 years, 1.43 years and 0.46 years for patients with dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively. Median overall survival (OS) following first-line treatment was 9.42, 5.22 and 0.72 years for dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively (p < 0.001). In a high-validity subcohort, OS did not differ significantly between RT:TN-CLL and dnDLBCL (median OS 9.85 years [CI: 9.16-10.70] for dnDLBCL, 6.07 years [CI: 4.23-not estimable] for RT:TN-CLL and 1.15 years [CI: 0.76-3.66] for RT:TE-CLL). In conclusion, patients with RT:TE-CLL had inferior TTNTd and OS compared to RT:TN-CLL and dnDLBCL. RT:TN-CLL demonstrated inferior TTNTd compared to dnDLBCL, but OS approached that of dnDLBCL. This indicates that for patients with RT:TN-CLL, chemoimmunotherapy may still be an effective modality, while patients with RT:TE-CLL need novel treatment options.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCell Transformation, NeoplasticFemaleHumansMaleMiddle Agedchronic lymphocytic leukaemiadiffuse large B‐cell lymphomaepidemiologyRichter transformation

Identifiers

PMID42381485
PMCPMC13570220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.